A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer.

Trial Profile

A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms NSABP-FB8
  • Most Recent Events

    • 07 Jul 2014 Status changed from active, no longer recruiting to completed asreported by ClinicalTrials.gov record.
    • 11 Oct 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014.as reported by ClinicalTrials.gov.
    • 24 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top